Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986242 + Nivolumab in Advanced Malignant Tumors
NCT03351231Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-986242 in solid tumor (advanced stage), sponsored by Bristol Myers Squibb. Started Nov 2017; status: terminated.
02
Drugs
BMS-986242
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03351231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351231.